Halseth, Amy E.

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 297

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 178

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 172

Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample

Dalton, M., Finlayson, G., Walsh, B., Halseth, A. E., Duarte, C., & Blundell, J. E. (2017) · International Journal of Obesity

Eating Disorders and BehaviorsPharmacology and Obesity Treatment

Cited by 60

Limitations to basal and insulin-stimulated skeletal muscle glucose uptake in the high-fat-fed rat

Halseth, A. E., Bracy, D. P., & Wasserman, D. H. (2000) · American Journal of Physiology-Endocrinology and Metabolism

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 57